{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
l-glutamine
to a specific field?
Status:
Investigational
Source:
NCT02125786: Phase 2 Interventional Active, not recruiting Ependymoma
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
METHIONINE C-11 is a synthetic amino acid radiolabeled with carbon-11. Acting as a methyl donor, methionine C 11 is incorporated into macromolecules, where it serves as a positron emission tomography (PET) imaging agent for detecting tumors with high rates of protein synthesis. METHIONINE C-11 is produced without any significant radiochemical impurities.
Status:
Investigational
Source:
NCT00124696: Phase 1 Interventional Completed Cocaine-Related Disorders
(2002)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cocaethylene is the ethyl ester of benzoylecgonine. Cocaethylene is formed in the liver after concurrent use of cocaine and alcohol. Cocaethylene works by blocking the dopamine transporter on dopaminergic presynaptic nerve terminals in the brain. It increases dopamine synaptic content, provoking enhanced postsynaptic receptor stimulation, resulting in euphoria, reinforcement, and self-administration. Compared to cocaine, which is a methyl ether of benzoylecgonine, cocaethylene has three to five times larger half-life in plasma. Cocaethylene is associated with seizures, liver damage and compromised the functioning of the immune system. It carries an 18-25 fold increase in risk for immediate death compared to cocaine alone.
Status:
Investigational
Source:
INN:ascorbyl gamolenate [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ascorbyl gamolenate, an aldehyde reductase inhibitor, participated in phase-I clinical trials for Diabetic neuropathies in the United Kingdom but these studies were discontinued.
Status:
Investigational
Source:
INN:elpetrigine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Elpetrigine (GW293273 or JZP-4) is potent calcium and sodium channel blocker. In animal models, elpetrigine exerts anxiolytic, anticonvulsant, antidepressant and antimania effects. Jazz Pharmaceuticals is developing elpetrigine for the treatment of mood disorders and epilepsy.
Status:
Investigational
Source:
NCT00082368: Phase 2 Interventional Completed Cancer
(2004)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Tariquidar, a non-competitive, specific P-glycoprotein (Pgp) inhibitor, is an anthranilamide derivative with multidrug resistance properties. Tariquidar binds to the ATP-binding cassette (ABC) transport protein Pgp, thereby inhibiting transmembrane transport of anticancer drugs resulting in their increased intracellular concentrations augmenting cytotoxicity of an anticancer drug. Tariquidar was discovered by Xenova Group and was developed for the treatment of multidrug resistance in cancer. In October 2002 the US Food
and Drug Administration (FDA) has granted fast track review status to tariquidar for the treatment of multi-drug resistance in first-line treatment of non-small cell lung cancer (NSCLC) patients. Tariquidar is still undergoing research as an adjuvant against multidrug resistance in cancer.
Status:
Investigational
Source:
NCT00006229: Phase 2/Phase 3 Interventional Completed Lung Cancer
(2000)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Rebimastat (BMS-275291) is a broad-spectrum matrix metalloproteinase (MMP) inhibitor free from toxicity-related inhibition of sheddases (cleaving membrane proteins at the cell surface). This MMP2 and MMP9 inhibitor may stop the growth of cancers by stopping blood flow to the tumor (stopping them from dividing). It might also block the enzymes necessary for growth of the tumor cell. Multiple phase II trials and a phase III clinical trial have been completed, testing the efficacy and safety of the compound in prostate cancer, HIV-related Kaposi’s Sarcoma, non-small cell lung cancer (phase II and III) and breast cancer.
Status:
Investigational
Source:
NCT00003667: Phase 2 Interventional Completed Sarcoma
(1998)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01200797: Phase 2 Interventional Terminated Recurrent Fallopian Tube Cancer
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
BN-2629 (also known as SJG-136 and SG2000), a dimeric pyrrolobenzodiazepine that binds in the minor groove of DNA and produces G-G interstrand cross-links via reactive N(10)-C(11)/N(10')-C(ll') imine/carbinolamine moieties. This drug was investigated in phase II clinical trials in patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer, however, these studied were terminated because of the slow accrual. In addition, BN-2629 participated in phase I/II trial in participants with advanced chronic lymphocytic leukemia and acute myeloid leukemia, but Spirogen also terminated these studies.
Status:
Investigational
Source:
NCT02674191: Not Applicable Interventional Unknown status Orthodontic Anchorage Procedures
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Dexivacaine is a local anesthetic drug that has minimal and non-significant side effects.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Argimesna (also known as arginine 2-mercaptoethanesulfonate) is a sulfhydryl group-containing molecule, which has no effect on glutathione status or on the total thiol pool, but is an uroprotective agent. Argimesna was investigated for the prevention of haemorrhagic cystitis from ifosfamide (IFO), but these studies were discontinued
